Technology & Economic Development
Growing Cornell Startups
The Kevin M. McGovern Family Center for Venture Development in the Life Sciences—established to assist Cornell high-potential, early-stage life science spin-off companies—welcomed its first client, Glycobia, in February 2012. In March, high-tech start-up DNANO Systems joined the client list. Seraph Robotics joined in June. DNANO’s tenure ended in April 2013, and SteriFreeMed joined in September 2013. ArcScan became a tenant in October 2013. The McGovern Center helps Cornell start-ups to prove their technologies, solidify management teams, strengthen business plans, and obtain investments to support the companies’ further growth.
- Glycobia
- Glycobia produces low-cost glycoengineering technology, which works by modifying common bacteria such as E. coli to directly produce human peptide, protein, and antibody drugs. The technology originated in the lab of Matthew DeLisa, Chemical and Biomolecular Engineering, where the team invented a novel method for engineering human therapeutic glycoproteins simply and quickly using E. coli bacteria as a platform.
- Visit Website →
- SteriFreeMed
- SteriFreeMed probes cold plasma technology applications for rapid room temperature sterilization. Cornell alumnus and former research associate Czeslaw Golkowski from the Department of Applied and Engineering Physics is the inventor and company CEO.
- Visit Website →
- ArcScan
- ArcScan pursues state-of-the-art ophthalmic imaging. The company’s ultra-high, ultrasound diagnostic device, Artemis III, maps a patient’s eye in comprehensive 3-D images. The medical instrument was developed at Weill Cornell Medical College.
- Visit Website →
- Seraph Robotics
- Seraph Robotics explores life science applications of the robotic 3-D printing technology platform, which descended from a Fab@Home project developed in the lab of Hod Lipson, Mechanical and Aerospace Engineering. The company is innovating a Fab@Home Model 3, a microindustrial robot designed for versatility.
- Visit Website →